generic sales boom in france

1
PharmacoEconomics & Outcomes News 256 - 1 Apr 2000 Generic sales boom in France Sales of nonbranded generic pharmaceutical products in France have skyrocketed in the 6 months following the introduction of a law in that country allowing pharmacists to substitute generic medicines for prescription brandname products, reports the Pharmaceutical Journal. Priced at about 30–40% below equivalent brandname products, generic sales are expected to grow by around £300 million this year, up from a turnover value of about £60 million in 1998. Generic sales have been particularly noticeable for certain medicines, including amoxicillin, for which generic versions of the drug account for 52% of total sales, and atenolol, for which 22% of sales are from generic products. Generic sales still represent only 2% of the French pharmaceutical market, compared with 40% in the US and 15% in the UK, notes the report. France benefits from new generic substitution rules. Pharmaceutical Journal 264: 427, 18 Mar 2000 800817067 1 PharmacoEconomics & Outcomes News 1 Apr 2000 No. 256 1173-5503/10/0256-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: tranliem

Post on 17-Mar-2017

214 views

Category:

Documents


0 download

TRANSCRIPT

PharmacoEconomics & Outcomes News 256 - 1 Apr 2000

Generic sales boom in FranceSales of nonbranded generic pharmaceutical products

in France have skyrocketed in the 6 months followingthe introduction of a law in that country allowingpharmacists to substitute generic medicines forprescription brandname products, reports thePharmaceutical Journal.

Priced at about 30–40% below equivalent brandnameproducts, generic sales are expected to grow by around£300 million this year, up from a turnover value of about£60 million in 1998. Generic sales have beenparticularly noticeable for certain medicines, includingamoxicillin, for which generic versions of the drugaccount for 52% of total sales, and atenolol, for which22% of sales are from generic products.

Generic sales still represent only 2% of the Frenchpharmaceutical market, compared with 40% in the USand 15% in the UK, notes the report.France benefits from new generic substitution rules. Pharmaceutical Journal 264:427, 18 Mar 2000 800817067

1

PharmacoEconomics & Outcomes News 1 Apr 2000 No. 2561173-5503/10/0256-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved